P
Phylogix
Biotechnology company focused on tissue protection and oncology
About Phylogix
Phylogix was a biotechnology firm established in 1999 by founder and CEO Jeff Moore.
Based in Waltham, United States, the company directed its efforts towards the development of small molecule-based therapeutics for oncology.
Phylogix's core scientific focus was on lectin-based therapeutic drugs designed for tissue protection and cancer treatment. The company's business model was centered on the research and development pipeline of these novel drug candidates, with the ultimate goal of bringing them to market, likely through partnerships or licensing agreements with larger pharmaceutical companies, a common strategy in the biotech sector.
The firm's lead product candidate was a therapeutic agent intended to shield bone marrow and the gastrointestinal tract from the severe toxic effects of chemotherapy. This product was in the pre-clinical stage of development. Despite its specific focus, Phylogix operated in a highly competitive field with numerous other companies, including Hummingbird Bioscience and Lyell Immunopharma. The company did not secure any public funding rounds and is now considered deadpooled, indicating a cessation of its operations.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 1998
- Headquarters
- Scarborough, United States
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2004 | $12M | $48M | Prospect Venture Partners · Radius Ventures · Atlas Venture · Prospect Venture Partners | — |
| SERIES AEquity / VC | Nov 2001 | $3M | $12M | BVF Partners | — |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
BVF Partners
Atlas Venture- PPProspect Venture Partners
Radius Ventures
Canaan
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Phylogix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phylogix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.